Evidence map›Paper›PMID 14999295›Full record

ArticleLeukemia2004

Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38- cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells.

M Kawakami, T Kimura, Y Kishimoto, T Tatekawa, Y Baba, T Nishizaki, N Matsuzaki, Y Taniguchi, S Yoshihara, K Ikegame and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Vasoactive intestinal peptide signaling axis in human leukemia.World journal of biological chemistry · 2011
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

M KawakamiDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan. mkawakami@cit.med.osaka-u.ac.jp
T Kimura
Y Kishimoto
T Tatekawa
Y Baba
T Nishizaki
N Matsuzaki
Y Taniguchi
S Yoshihara
K Ikegame
T Shirakata
S Nishida
T Masuda
N Hosen
A Tsuboi
Y Oji
Y Oka
H Ogawa
Y Sonoda
H Sugiyama
I Kawase
T Soma
Osaka University · JPKyoto Prefectural University of Medicine · JPIkeda Municipal Hospital · JPKinki Central Hospital · JPOklahoma Medical Research Foundation · USOsaka Medical Center for Cancer and Cardiovascular Diseases · JPOsaka Minami Medical Center · JPSuita Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primitive hematopoietic progenitor cells such as severe combined immunodeficiency- repopulating cells and long-term culture-initiating cells are enriched in CD34+CD38- cells derived from various stem cell sources. In this study, to elucidate the features of such primitive cells at the molecular level, we tried to isolate genes that were preferentially expressed in umbilical cord blood (CB)-derived CD34+CD38- cells by subtractive hybridization. The gene for VPAC1 receptor, a receptor for the neuropeptide vasoactive intestinal peptide (VIP), was thereby isolated and it was shown that this gene was expressed in both CD34+CD38- and CD34+CD38+ CB cells and that the expression levels were higher in CD34+CD38- CB cells. Next, we assessed the effects of VIP on the proliferation of CD34+ CB cells using in vitro culture systems. In serum-free single-cell suspension culture, VIP enhanced clonal growth of CD34+ CB cells in synergy with FLT3 ligand (FL), stem cell factor (SCF), and thrombopoietin (TPO). In serum-free clonogenic assays, VIP promoted myeloid (colony-forming unit-granulocyte/macrophage (CFU-GM)) and mixed (CFU-Mix) colony formations. Furthermore, in Dexter-type long-term cultures, VIP increased colony-forming cells at week 5 of culture. These results suggest that VIP functions as a growth-promoting factor of CB-derived hematopoetic progenitor cells.

Indexed as

ADP-ribosyl CyclaseADP-ribosyl Cyclase 1Antigens, CDAntigens, CD34Blotting, SouthernCell DivisionCells, CulturedFetal BloodHematopoietic Stem CellsHumansMembrane GlycoproteinsReceptors, Vasoactive Intestinal PeptideReceptors, Vasoactive Intestinal Polypeptide, Type IVasoactive Intestinal PeptideADP-ribosyl CyclaseADP-ribosyl Cyclase 1Antigens, CDAntigens, CD34CD38 protein, humanMembrane GlycoproteinsReceptors, Vasoactive Intestinal PeptideReceptors, Vasoactive Intestinal Polypeptide, Type IVasoactive Intestinal Peptide

Identifiers

PMID14999295
OpenAlexW2052894073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.